Bain Capital Life Sciences Opportunities III, LP

Overview

• HeadquartersBoston, United States²
• Legal formLimited Partnership²
• Kind of organizationLimited partnership²
• LEI254900HJSWKW7OXGFX09²
• StatusActive²
• LEI statusIssued and current²
• Registered addressC/O Maples Fiduciary Services (Delaware) Inc., 19807 Wilmington, United States²
• Registered withDivision of Corporations, Department of State, 5999659²

See how the biggest companies compare on our leaderboards

Corporate structure

Bain Capital Life Sciences Opportunities III, LP sits at the top of its group. 6 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); stakes of 5% or more it reported on Schedules 13D and 13G (5 companies). Each entity in the chart links to its source.

Timeline

1. Jun 14, 2021Founded Bain Capital Life Sciences Opportunities III, LP is founded²

Filings

18 filings to the SEC since October 2021: 18 other. The latest 18:

1. Aug 31, 2026N-PX EDGAR
2. Aug 14, 202613F-NT EDGAR
3. May 15, 202613F-NT EDGAR
4. Feb 17, 202613F-NT EDGAR
5. Nov 14, 202513F-NT EDGAR
6. Aug 29, 2025N-PX EDGAR
7. Aug 14, 202513F-NT EDGAR
8. May 15, 202513F-NT EDGAR
9. Feb 14, 202513F-NT EDGAR
10. Nov 14, 202413F-NT EDGAR
11. Aug 30, 2024N-PX EDGAR
12. Aug 12, 202413F-NT EDGAR
13. May 15, 202413F-NT EDGAR
14. Feb 13, 202413F-NT EDGAR
15. Nov 14, 202313F-NT EDGAR
16. Aug 14, 202313F-NT EDGAR
17. May 15, 202313F-NT EDGAR
18. Feb 14, 202313F-NT EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Stakes it holds

Bain Capital Life Sciences Opportunities III, LP has told the SEC it owns more than 5% of 5 companies, latest first (Schedules 13D and 13G).

• Cabaletta Bio, Inc.SCHEDULE 13G/A Jun 1, 2023 to Aug 14, 2026³
• Kyverna Therapeutics, Inc.SCHEDULE 13G/A Feb 14, 2024 to Aug 14, 2026⁴
• Century Therapeutics (United States)SCHEDULE 13G/A Apr 25, 2024 to Nov 14, 2025⁵
• Disc Medicine, Inc.SCHEDULE 13G/A Feb 24, 2023 to Feb 14, 2025⁶
• Tvardi Therapeutics, Inc.SC 13G/A Nov 18, 2022 to Feb 13, 2024⁷